Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HY05350 injection in MSLN-positive advanced solid tumors
CTR20252631Phase 2Active
- Sponsor
- Huiyu Haiyue
- Start
- Aug 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HY05350 in Nonhematologic neoplasms, sponsored by Huiyu Haiyue. Started Aug 2025; status: active.
02
Drugs
HY05350
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20252631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252631.